High-Alert Medications—Insulin and Vasopressors: Practical Strategies in Pursuit of Safety
Although most medications in healthcare today have a wide margin of safety, there remains some which can cause serious harm or death if they are misused. To reduce the risk of error with these “high-alert” medications, special precautions and high leverage strategies should be implemented to avoid serious patient safety events. Many organizations have taken steps to identify these medications, but many are still less than confident that they have taken all the necessary precautions with high-alert drugs against serious patient harm.
Join the ISMP faculty as we examine and define the importance of high-alert medications as part of routine patient care and review the results of ISMP Medication Safety Self Assessment® for High-Alert Medications with particular attention to vasopressors and insulin. Faculty will review specific safety characteristics of each these important drug classes, describe self-assessment findings related to the use of these medications, and discuss the necessary strategies for harm prevention when using these medications.
Pharmacists, Physicians, Nurses, PAs, CRNAs
Medication Safety Officers
Leaders in Pharmacy and Nursing
Pharmacy and Anesthesia Technicians
Following completion of this activity, participants will be able to:
Define high-alert medications and their impact on patient safety.
Describe the low scoring assessment items for insulin from the ISMP Medication Safety Self Assessment® for High-Alert Medications.
Cite at least two effective strategies each for harm prevention for vasopressors and insulin.
Rita Jew, PharmD, MBA, BCPPS, FASHP, Vice President of Operations, ISMP
Matthew Grissinger, RPh, FISMP, FASCP, Director of Error Reporting Programs, ISMP
This activity is funded by Baxter.
Pharmacists and Pharmacy Technicians
This CE activity is jointly provided by ProCE, LLC and the Institute for Safe Medication Practices (ISMP). ProCE is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-21-287-L05-P/T has been assigned to this knowledge-based live CE activity (initial release date December 16, 2021). This CE activity is approved for 1.25 contact hours (0.125 CEU) in states that recognize ACPE providers. This CE activity is provided at no cost to participants. Successful completion of the online post-test and evaluation at www.ProCE.com no later than January 14, 2022 is required to receive CE credit. CE credit will be automatically uploaded to NABP/CPE Monitor upon completion of the post-test and evaluation. No partial credit will be given. Conflict of interest disclosures are required of all faculty and shall be provided to all participants at the conference.
This activity has been approved for up to 1.25 California State Nursing contact hours by the provider, Debora Simmons, who is approved by the California Board of Registered Nursing, Provider Number CEP 13677. Credit will only be issued to individuals that are individually registered and attend the entire program.
This meeting has been approved for a total of 1.0 contact hours of Continuing Education Credit toward fulfillment of the requirements of ASHRM designations of FASHRM (Fellow) and DFASHRM (Distinguished Fellow) and towards CPHRM renewal. CPHRM Content Outline Category 1 Clinical/Patient Safety.